Skip to content

Comparative Evaluation of Collagen Sponge with recombinant bone morphogenic protein 2 for Alveolar Ridge Preservation: A Pilot Clinical Study

Comparative Evaluation of Collagen Sponge with recombinant bone morphogenic protein 2 for Alveolar Ridge Preservation: A Pilot Clinical Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240715009
Enrollment
16
Registered
2024-07-15
Start date
2023-10-31
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enrolled the healthy patient who need to extract the single-tooth extraction in the premolar tooth due to unrestorable (caries, fracture, or orthodontic treatment) with an intact buccal bone plate (more than 50%) Alveolar ridge preservation, rhBMP-2, Collagen.

Interventions

Local anesthesia (2% lidocaine with epinephrine 1:105 in a quantity, 1-2 cartridges), was administered, and the tooth was atraumatic extracted. The extraction wound was cleaned with 0.9% NSS. In the e
Ethicon, Norderstedt, Germany). Both groups followed the same postoperative care regimen: postoperative antibiotics (amoxicillin 500 mg) were prescribed every 8 hours for 5 days and ibuprofen 400 mg
Experimental Drug,No Intervention No treatment
Absorbable collagen sponge(ACS)/rhBMP-2,No treatment/ Standard of care

Sponsors

Thailand Science Research and Innovation (TSRI), and National Science, Research and Innovation Fund (NSRF)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: The healthy patient who need to extract the single-tooth extraction in the premolar tooth due to unrestorable (caries, fracture, or orthodontic treatment) with an intact buccal bone plate (more than 50% Healthy adults patient (20 years or older) and able to sign an informed consent form. All extraction sites have a keratinized gingival tissue in a minimum width of 2 mm

Exclusion criteria

Exclusion criteria: Presence of periodontal disease. History of smoking, radiotherapy, or chemotherapy within the past 5 years Pregnancy or breastfeeding. Previous or current medication e.g. steroids, antiresorptive drugs including affecting on bone remodelling phase. General contraindications for surgical treatment including antiplatelet or anticoagulation drugs. Allergy to collagen

Design outcomes

Primary

MeasureTime frame
Bone reduction 12 weeks Mean difference bone reduction

Secondary

MeasureTime frame
Clinical evaluation 12 weeks Soft tissue healing

Countries

Thailand

Contacts

Public ContactPawornwan Rittipakorn

Suranaree University of Technology

r.paw@g.sut.ac.th0650979555

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026